RIPK1 and neoplasm: Indeed, the activation of RIPK1/RIPK3 leads to the upregulation of inflammatory chemokines that promote the cross-priming of CD8+ T cell vaccination responses [11–13]; the presence of intratumoral chemokines is positively correlated with cytotoxic CD8+ T cell (CTL) infiltration [14] indicating that the activation of necroptosis signaling provides anti-tumor immunity.